Trials / Completed
CompletedNCT02537301
Endoscopic Retrograde Cholangiopancreatography(ERCP)-Related Discussion Through a Mobile Social App by a Group of Doctors
Endoscopic Retrograde Cholangiopancreatography(ERCP)-Related Discussion Through a Mobile Social App by Trainees After Finishing ERCP Training
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 60 (estimated)
- Sponsor
- Air Force Military Medical University, China · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Group chat through the platform of mobile social networking provides an easily accessible, real-time and interactive channel for communication. With the help of mobile social app, a group of doctors with similar interests can share valuable cases, important papers and opinions through multiple media types (texts, images, and videos). It remains unknown what activities of Endoscopic Retrograde Cholangiopancreatography(ERCP) doctors on a group-chat platform are. In the beginning of 2013, a chatting group on Wechat (the most popular mobile social app in China), focusing on ERCP, was created. All the doctors who received and finished their ERCP training in Xijing Hospital of Digestive Diseases were invited to join in the platform. The contents in the chatting group were analyzed. The relationships between the chatting activities of ERCP doctors and the performance of ERCP (such as case volume, cannulation success rate and PEP etc.) were investigated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | joining in the platform | The activities (contents, chatting frequency etc.) of ERCP doctors on the chatting group were retrospectively extracted. The data related to the performance of ERCP (such as case volume, cannulation success rate and PEP etc.) by ERCP doctors were collected by a questionaire. |
Timeline
- Start date
- 2015-06-01
- Primary completion
- 2016-01-01
- Completion
- 2016-01-01
- First posted
- 2015-09-01
- Last updated
- 2016-01-12
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02537301. Inclusion in this directory is not an endorsement.